Guardant Health (NASDAQ:GH) Stock Purchase Reported by Rep. Jonathan L. Jackson

Representative Jonathan L. Jackson (Democratic-Illinois) recently bought shares of Guardant Health, Inc. (NASDAQ:GH). In a filing disclosed on October 19th, the Representative disclosed that they had bought between $15,001 and $50,000 in Guardant Health stock on September 28th. The trade occurred in the Representative’s “MORGAN STANLEY TRUST ACCOUNT” account.

Representative Jonathan L. Jackson also recently made the following trade(s):

• Purchased $50,001 – $100,000 in shares of Estee Lauder Companies (NYSE:EL) on 9/28/2026.
• Sold $50,001 – $100,000 in shares of Viasat (NASDAQ:VSAT) on 9/28/2026.
• Sold $50,001 – $100,000 in shares of Walmart (NASDAQ:WMT) on 9/28/2026.
• Purchased $50,001 – $100,000 in shares of Datadog (NASDAQ:DDOG) on 9/28/2026.
• Sold $1,001 – $15,000 in shares of Tortoise Energy Infrastructure (NYSE:TYG) on 9/4/2026.
• Sold $1,001 – $15,000 in shares of Viasat (NASDAQ:VSAT) on 8/28/2026.

Guardant Health Stock Up 2.5%

Shares of NASDAQ GH opened at $166.66 on Thursday. The firm’s 50-day simple moving average is $167.73 and its 200 day simple moving average is $141.01. The company has a market cap of $22.37 billion, a price-to-earnings ratio of -47.75 and a beta of 1.58. Guardant Health, Inc. has a 12-month low of $66.59 and a 12-month high of $191.05.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.34. The company had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. During the same quarter in the previous year, the business posted ($0.44) EPS. The company’s revenue was up 44.3% compared to the same quarter last year. On average, equities analysts expect that Guardant Health, Inc. will post -3.02 earnings per share for the current year.

Institutional Trading of Guardant Health

A number of hedge funds and other institutional investors have recently modified their holdings of GH. The Manufacturers Life Insurance Company acquired a new position in Guardant Health during the second quarter valued at approximately $208,592,000. William Blair Investment Management LLC acquired a new position in shares of Guardant Health during the 2nd quarter worth approximately $196,737,000. First Light Asset Management LLC increased its position in shares of Guardant Health by 57.5% during the 2nd quarter. First Light Asset Management LLC now owns 441,586 shares of the company’s stock worth $66,251,000 after purchasing an additional 161,287 shares during the last quarter. Orbimed Advisors LLC acquired a new position in shares of Guardant Health during the 1st quarter worth approximately $40,199,000. Finally, Sei Investments Co. raised its stake in shares of Guardant Health by 30.2% during the 1st quarter. Sei Investments Co. now owns 341,013 shares of the company’s stock worth $31,499,000 after purchasing an additional 79,071 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on GH. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research note on Thursday, October 15th. Guggenheim upped their price target on shares of Guardant Health from $190.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, October 1st. UBS Group increased their price objective on shares of Guardant Health from $175.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Piper Sandler reissued an “overweight” rating on shares of Guardant Health in a research report on Tuesday, September 15th. Finally, Morgan Stanley raised their price objective on shares of Guardant Health from $185.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and an average price target of $190.00.

Insider Activity at Guardant Health

In other news, insider Terilyn Monroe sold 46,300 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total value of $7,645,056.00. Following the completion of the sale, the insider owned 22,979 shares of the company’s stock, valued at approximately $3,794,292.48. This represents a 66.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Amirali Talasaz sold 37,500 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $169.16, for a total transaction of $6,343,500.00. Following the transaction, the chief executive officer owned 37,500 shares in the company, valued at approximately $6,343,500. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 178,940 shares of company stock worth $30,070,911. Insiders own 5.60% of the company’s stock.

About Representative Jackson

Jonathan Jackson (Democratic Party) is a member of the U.S. House, representing Illinois’ 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Jackson (Democratic Party) is running for re-election to the U.S. House to represent Illinois’ 1st Congressional District. He declared candidacy for the 2026 election.

Jonathan Jackson was born in Chicago, Illinois. Jackson graduated from Whitney Young High School. He earned an M.B.A. from Northwestern University. Jackson’s career experience includes working as an investment analyst and an entrepreneur.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.